Seleniso (Silvio) manufacturer and drug background introduction

Selinexor () is an oral selective nuclear export inhibitor (SINE), mainly used to treat relapsed or refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (NHL). The drug was developed by Karyopharm Therapeutics of the United States. This company focuses on the development of targeted innovative drugs in the field of tumors, especially in the nuclear export inhibition mechanism. The launch of selinesol marks an important breakthrough for the company in the field of new anti-tumor mechanism drugs.

In terms of drug background, selinesol is one of the first approved oral selective nuclear export inhibitors. By inhibiting the function of nuclear export protein XPO1 (Exportin-1), selinesol causes tumor suppressor proteins to accumulate in the nucleus, thereby inducing cancer cell apoptosis. Its unique mechanism of action enables it to show significant efficacy in relapsed or refractory hematological malignancies, especially providing a new treatment option for patients who are resistant to traditional treatment options.

In the international market, selinesol has been approved by the U.S. FDA for the treatment of multiple myeloma, and is also in the approval or clinical application stage in Europe and some Asian countries. Clinical trials have shown that selinesol combined with low-dose dexamethasone can achieve a considerable objective response rate (ORR) in patients with relapsed/refractory multiple myeloma, bringing significant survival benefits to refractory patients. This clinical data establishes its important position in the treatment of hematological malignancies.

In terms of production and drug quality, Karyopharm Therapeutics strictly follows GMP standards to produce selinesol to ensure drug purity, stability and controllable bioavailability. In addition, medicines are distributed and supplied by multiple partners around the world to ensure that patients can obtain medicines through formal channels. Overall, selinesol has become one of the important drugs in the field of hematological cancer treatment with its innovative mechanism, clinical efficacy and high-quality production standards, and provides new treatment hope for patients with drug resistance or relapse.

Reference link:https://www.drugs.com